Cancer Control & Survivorship
Wilmot scientists have been conducting Cancer Control research for more than 40 years. Our program is one of the oldest and most highly regarded in the field and has been continuously funded since 1983.
The National Cancer Institute chose Wilmot as one of only two cancer centers in the U.S. to serve as a research hub for NCORP, which stands for the NCI Community Oncology Research Program. In this role, our Cancer Control researchers design and manage clinical studies that are implemented nationwide.
Survivorship research has become a national priority as millions of people live actively with cancer or achieve years of remission. Wilmot remains well-positioned to continue to contribute to this field with a wide variety of investigations:
- Exercise and cancer. The PEAK Lab is a core facility at the heart of our efforts to study the impact of exercise (walking, gentle yoga, resistance bands, for example) on cancer patients before, during, and after treatment. Wilmot scientists have shown that exercise is better than medications at reducing cancer-related fatigue, the chief complaint of many patients.
- Treatment-related cognitive impairment. Also known as “chemo-brain,” we have a strong focus on this condition, led by our Cancer Control & Psychoneuroimmunology Lab. Our scientists have already been leaders in proving that this condition is pervasive among women with breast cancer, and now are studying the role of inflammation and other biological factors, how to predict who might be most at risk, and potential treatments.
- Vitamins and supplements. Over the years we have investigated various vitamins and supplements to learn if they can ease side effects of cancer treatment or improve outcomes. Currently our focus in on studies of vitamin D and omega-3 fatty acids.
- . Since cancer often afflicts older adults, aging is a significant factor in survivorship. Wilmot has one of the nation’s few geriatric oncology teams with a specialized clinic that aids in research. Their goal is to provide evidence-based new models of care for people 70 years old and older. Several of our basic scientists are also studying aging cells and how they respond to treatment.